[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

September 2017 | 137 pages | ID: GC0AE688788EN
GlobalData

US$ 4,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

SUMMARY

This report provides insight into the diversifying and highly lucrative diabetes mellitus (DM) market. Analysis has identified a high level of diversification in the market, which is of vital importance for investors and key market players. Furthermore, the report provides insight into groundbreaking drugs, and the threats that they are likely to encounter over the forecast period. Also identified are opportunities for investment and co-marketing in key BRIC economies, where the yearly incidence of T1DM is set to exceed the total number of T1DM patients in the US.

This report also comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

There is a high unmet clinical need to develop favorable routes of administration for insulin products. Likewise, there is high unmet need for a curative or prophylactic treatment for both T1DM and T2DM.

There are currently over 800 products in the DM pipeline, with developmental molecules generally being aimed at improving on existing products. Most pipeline molecules are insulin or GLP-1 agonists. There are several combination therapy trials for the use of insulin receptor/GLP-1 agonists with other compounds - particularly SGLT-2 inhibitors. Among these products, an entirely novel SGLT1/2 inhibitor is expected to enter the market, and is expected to become a blockbuster drug, achieving licensed status for both T1DM and T2DM.

SCOPE
  • Global revenue from the DM market between 2016 and 2023
  • Novel compounds and new drugs achieving blockbuster status by 2023
  • Analysis of market share changes for leading compounds by 2023
  • Analysis of leading companies by market share
  • Analysis of deals conducted during the 2006-2017 period
REASONS TO BUY
  • Understand the current treatment landscape, with profile assessments of key marketed products and a focus on historical and forecast sales patterns.
  • Gain insight into a highly diversifying market for DM products, and the factors behind the significant changes projected in market share between key compounds.
  • Analyze the DM pipeline through a comprehensive review of products, segmented by stage of development, molecule type and molecular target - as well as detailed profile assessments and multi-scenario revenue projections for the most promising late-stage pipeline candidates.
  • Consider market opportunities and potential risks associated with attempting to bring pipeline products to market by examining trends in clinical trial size, duration and failure rate by stage of development, key indication, molecule type and molecular target.
  • Predict growth in market size, with multi-scenario forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the DM market and understand the factors that will influence growth and market share with profile assessments of key companies, including multi-scenario revenue projections.
  • Identify commercial opportunities in the DM deals landscape by analyzing trends in licensing and co-development deals.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Overview
2.2 Classification of Diabetes
2.3 Symptoms
2.4 Diagnostic Criteria
2.5 Etiology
  2.5.1 T1DM
  2.5.2 T2DM
2.6 Pathophysiology
  2.6.1 Physiology of Glucose Metabolism
  2.6.2 T1DM Pathophysiology
  2.6.3 T2DM Pathophysiology
2.7 Epidemiology
  2.7.1 T1DM
  2.7.2 T2DM
2.8 Comorbidities and Complications
2.9 Treatments
  2.9.1 Insulin Therapy
  2.9.2 Insulin Secretagogues
  2.9.3 Thiazolidinediones
  2.9.4 Biguanides
  2.9.5 Dipeptidyl Peptidase 4 Inhibitors
  2.9.6 Glucagon-Like Peptide-1 Receptor Agonists
  2.9.7 Sodium-Glucose Co-Transporter-2 Inhibitors
  2.9.8 Amylin Analogs
  2.9.9 Combination Therapies
  2.9.10 Non-pharmacological Therapy

3 KEY MARKETED PRODUCTS

3.1 Overview
  3.1.1 Market Share of the Top Five Grossing Drugs in 2016
  3.1.2 Market Share of the Five Strongest Growing Blockbuster Drugs
3.2 Long-Acting Insulin Therapies (Basal Insulins)
  3.2.1 Lantus (insulin glargine) - Sanofi
  3.2.2 Levemir (insulin detemir) - Novo Nordisk
  3.2.3 Tresiba (insulin degludec) - Novo Nordisk
  3.2.4 Toujeo (insulin glargine) - Sanofi
3.3 Short-Acting Insulin Therapies (Bolus Insulins)
  3.3.1 Humalog (insulin lispro) - Eli Lilly
  3.3.2 Novolog (Insulin aspart) - Novo Nordisk
  3.3.3 Apidra (insulin glulisine) - Sanofi
3.4 GLP-1 Receptor Agonists
  3.4.1 Victoza (liraglutide) - Novo Nordisk
  3.4.2 Trulicity (dulaglutide) - Eli Lilly
3.5 DPP-4 Inhibitors
  3.5.1 Januvia (sitagliptin) - Merck and Co
  3.5.2 Galvus (vildagliptin) - Novartis
  3.5.3 Tradjenta (linagliptin) - Boehringer Ingelheim
3.6 SGLT-2 Inhibitors
  3.6.1 Invokana (canagliflozin) - Johnson and Johnson
  3.6.2 Jardiance (empagliflozin) - Boehringer Ingelheim
  3.6.3 Farxiga (dapagliflozin) - AstraZeneca
3.7 Combination Therapies
  3.7.1 Soliqua 100/33 (insulin glargine and lixisenatide) - Sanofi
  3.7.2 Xultophy (insulin degludec and liraglutide) - Novo Nordisk
  3.7.3 Janumet - Merck
  3.7.4 Qtern (saxagliptin and dapagliflozin) - AstraZeneca
3.8 Unmet Needs
3.9 Conclusion

4 PIPELINE LANDSCAPE ASSESSMENT

4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
  4.4.1 Clinical Trial Failure Rates
  4.4.2 Clinical Trial Duration
  4.4.3 Clinical Trial Size
  4.4.4 Aggregate Clinical Program Size
4.5 Assessment of Key Pipeline Products
  4.5.1 Semaglutide (NN-9535) - Novo Nordisk
  4.5.2 Oral Semaglutide (OG-217SC) - Novo Nordisk
  4.5.3 ITCA 650 - Intarcia
  4.5.4 Sotagliflozin - Lexicon Pharmaceuticals and Sanofi
  4.5.5 Ertugliflozin - Merck and Co and Pfizer

5 MULTI-SCENARIO MARKET FORECAST TO 2023

5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
  5.3.1 Insulin Receptors
  5.3.2 GLP-1 Receptors
  5.3.3 SGLT-2 Inhibitors
  5.3.4 DPP-4 Inhibitors

6 COMPANY ANALYSIS AND POSITIONING

6.1 Revenue and Market Share Analysis by Company
  6.1.1 Novo Nordisk - Sales from Recently Approved and Upcoming Products to Increase Already Substantial Market Share
  6.1.2 Eli Lilly - Strong Growth to Result in Elevation to Second Place in Market
  6.1.3 Sanofi - Large Market Share Loss Due to Declining Sales of Lantus
  6.1.4 AstraZeneca - Growth in Revenue Largely Attributable to Farxiga Sales
  6.1.5 Johnson and Johnson - Continued Uptake of Invokana to Drive Market Growth
  6.1.6 Merck & Co - Patent Expiry of Januvia to Limit Growth
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 STRATEGIC CONSOLIDATIONS

7.1 Licensing deals
  7.1.1 Deals by Region, Value and Year
  7.1.2 Deals by Stage of Development and Value
  7.1.3 Deals by Molecule Type and Molecular Target
  7.1.4 Licensing Deals Valued at $100m or above
7.2 Co-Development Deals
  7.2.1 Deals by Region, Value and Year
  7.2.2 Deals by Stage of Development and Value
  7.2.3 Deals by Molecule Type and Molecular Target
  7.2.4 Co-development Deals Valued at $100m and above

8 APPENDIX

8.1 References
8.2 Abbreviations
8.3 List of All Pipeline Products
8.4 Disease List
8.5 Methodology
  8.5.1 Coverage
  8.5.2 Secondary Research
  8.5.3 Market Size and Revenue Forecasts
  8.5.4 Pipeline Analysis
  8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer

LIST OF TABLES

Table 1: Diabetes Drugs Market, Global, Approved Indications for Lantus, 2017
Table 2: Diabetes Drugs Market, Global, Approved Indications for Levemir, 2017
Table 3: Diabetes Drugs Market, Global, Approved Indications for Tresiba, 2017
Table 4: Diabetes Drugs Market, Global, Approved Indications for Toujeo, 2017
Table 5: Diabetes Drugs Market, Global, Approved Indications for Humalog, 2017
Table 6: Diabetes Drugs Market, Global, Approved Indications for Novolog, 2017
Table 7: Diabetes Drugs Market, Global, Approved Indications for Apidra, 2017
Table 8: Diabetes Drugs Market, Global, Approved Indications for Victoza, 2017
Table 9: Diabetes Drugs Market, Global, Approved Indications for Trulicity, 2017
Table 10: Diabetes Drugs Market, Global, Approved Indications for Januvia, 2017
Table 11: Diabetes Drugs Market, Global, Approved Indications for Galvus, 2017
Table 12: Diabetes Drugs Market, Global, Approved Indications for Tradjenta, 2017
Table 13: Diabetes Drugs Market, Global, Approved Indications for Invokana, 2017
Table 14: Diabetes Drugs Market, Global, Approved Indications for Jardiance, 2017
Table 15: Diabetes Drugs Market, Global, Approved Indications for Farxiga, 2017
Table 16: Diabetes Drugs Market, Global, Approved Indications for Soliqua, 2017
Table 17: Diabetes Drugs Market, Global, Approved Indications for Xultophy, 2017
Table 18: Diabetes Drugs Market, Global, Approved Indications for Janumet, 2017
Table 19: Market, Global, Approved Indications for Qtern, 2017
Table 20: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (Part 1)
Table 21: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (Part 2)
Table 22: Diabetes Drugs Market, Global, Generic Usage Across Key Indications, 2017
Table 23: Diabetes Drugs Market, Global, Annual Revenue within Diabetes by Company, 2016-2023
Table 24: Abbreviations

LIST OF FIGURES

Figure 1: Diabetes Drugs Market, Global, Epidemiology Patterns for T1DM, 2016-2023
Figure 2: Diabetes Drugs Market, Global, Epidemiology Patterns for T2DM, 2016-2023
Figure 3: Diabetes Drugs Market, Global, Market Share Projections for Key Established Products, 2016-2023
Figure 4: Diabetes Drugs Market, Global, Market Share Projections for Key Upcoming Products, 2016-2023
Figure 5: Diabetes Drugs Market, Global, Percentage Change in Market Share for Key Products 2016-2023
Figure 6: Diabetes Drugs Market, Global, Key Marketed Products and Approved Indications, 2017
Figure 7: Diabetes Drugs Market, Global, Annual Revenue for Lantus ($bn), 2006-2023
Figure 8: Diabetes Drugs Market, Global, Annual Revenue for Levemir ($bn), 2006-2023
Figure 9: Diabetes Drugs Market, Global, Annual Revenue for Tresiba ($bn), 2016-2023
Figure 10: Diabetes Drugs Market, Global, Annual Revenue for Toujeo ($bn), 2015-2023
Figure 11: Diabetes Drugs Market, Global, Annual Revenue for Humalog ($bn), 2006-2023
Figure 12: Diabetes Drugs Market, Global, Annual Revenue for Novolog ($bn), 2006-2023
Figure 13: Diabetes Drugs Market, Global, Annual Revenues for Apidra ($m), 2009-2023
Figure 14: Diabetes Drugs Market, Global, Annual Revenues for Victoza ($bn), 2009-2023
Figure 15: Diabetes Drugs Market, Global, Annual Revenue for Trulicity ($bn), 2014-2023
Figure 16: Diabetes Drugs Market, Global, Annual Revenue for Januvia ($bn), 2006-2023
Figure 17: Diabetes Drugs Market, Global, Annual Revenue for Galvus ($bn), 2007-2023
Figure 18: Figure 17: Diabetes Drugs Market, Global, Annual Revenues for Tradjenta ($m), 2011-2023
Figure 19: Diabetes Drugs Market, Global, Annual Revenues for Invokana ($bn), 2013-2023
Figure 20: Diabetes Drugs Market, Global, Annual Revenue for Jardiance ($bn), 2014-2023
Figure 21: Diabetes Drugs Market, Global, Annual Revenue for Farxiga ($bn), 2013-2023
Figure 22: Diabetes Drugs Market, Global, Annual Revenues for Soliqua 100/33 ($m), 2017-2023
Figure 23: Diabetes Drugs Market, Global, Annual Revenue for Xultophy ($bn), 2017-2023
Figure 24: Diabetes Drugs Market, Global, Annual Revenue for Janumet ($bn), 2007-2023
Figure 25: Diabetes Drugs Market, Global, Annual Revenue for Qtern ($m), 2017-2023
Figure 26: Diabetes Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 27: Diabetes Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
Figure 28: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Stage of Development, 2017
Figure 29: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecule Type, 2017
Figure 30: Diabetes Drugs Market, Global, Pipeline by Molecular Target, 2017
Figure 31: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecular Target, 2017
Figure 32: Diabetes Drugs Market, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2017
Figure 33: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Indication (%), 2006-2017
Figure 34: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecule Type (%), 2006-2017
Figure 35: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecular Target (%), 2006-2017
Figure 36: Diabetes Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 37: Diabetes Drugs Market, Global, Clinical Trial Duration by Indication and Stage of Development (months), 2006-2017
Figure 38: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017
Figure 39: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017
Figure 40: Diabetes Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006-2017
Figure 41: Diabetes Drugs Market, Global, Clinical Trial Size by Indication and Stage of Development (participants), 2006-2017
Figure 42: Diabetes Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2017
Figure 43: Diabetes Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (Participants), 2006-2017
Figure 44: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development, 2006-2017
Figure 45: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Indication and Stage of Development (participants), 2006-2017
Figure 46: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017
Figure 47: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017
Figure 48: Diabetes Drugs Market, Global, Revenue Forecast for Semaglutide (NN-9535) ($bn), 2017-2023
Figure 49: Diabetes Drugs Market, Global, Revenue Forecast for Oral Semaglutide (OG-217SC) ($bn), 2020-2023
Figure 50: Diabetes Drugs Market, Global, Revenue Forecast for ITCA 650 ($bn), 2018-2023
Figure 51: Diabetes Drugs Market, Global, Revenue Forecast for Sotagliflozin ($bn), 2018-2023
Figure 52: Diabetes Drugs Market, Global, Revenue Forecast for Ertugliflozin ($m), 2017-2023
Figure 53: Diabetes Drugs Market, Global, Annual Revenue Forecast, 2016-2023
Figure 54: Diabetes Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016-2023
Figure 55: Diabetes Drugs Market, Global, Annual Revenue Forecast for Insulin Receptors ($bn), 2016-2023
Figure 56: Diabetes Drugs Market, Global, Annual Revenue Forecast for GLP-1 Receptors, 2016-2023
Figure 57: Diabetes Drugs Market, Global, Annual Revenue Forecast for SGLT-2 Inhibitors, 2016-2023
Figure 58: Diabetes Drugs Market, Global, Annual Revenue Forecast for DPP-4 Inhibitors, 2016-2023
Figure 59: Diabetes Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023
Figure 60: Diabetes Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 61: Diabetes Drugs Market Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 62: Diabetes Drugs Market, Global, Revenue by Route of Acquisition, 2016-2023
Figure 63: Diabetes Drugs Market, Global, Novo Nordisk Annual Revenue Forecast, ($bn), 2016-2023
Figure 64: Diabetes Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2016-2023
Figure 65: Diabetes Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016-2023
Figure 66: Diabetes Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
Figure 67: Diabetes Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2016-2023
Figure 68: Diabetes Drugs Market, Global, Merck and Co Annual Revenue Forecast ($bn), 2016-2023
Figure 69: Diabetes Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2016-2023
Figure 70: Diabetes Drugs Market, Global, Pipeline Developers by Level of Diabetes Specialization, 2016-2023
Figure 71: Diabetes Drugs Market, Global, Proportion of Total Company Revenue Attributable to Diabetes, 2016-2023
Figure 72: Diabetes Drugs Market, Licensing Deals by Region, Value and Year, 2006-2017
Figure 73: Diabetes Drugs Market, Global, Number of Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 74: Diabetes Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017
Figure 75: Diabetes Drugs Market, Global, Licensing Deals Valued at $100m and above, 2006-2017
Figure 76: Diabetes Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006-2017
Figure 77: Diabetes Drugs Market, Global, Number of Co-development Deals by Value and Stage of Development, 2006-2017
Figure 78: Diabetes Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2017
Figure 79: Diabetes Drugs Market, Global, Co-development Deals Valued at $100m and above, 2006-2017
Figure 80: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 1)
Figure 81: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 2)
Figure 82: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 3)
Figure 83: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 4)
Figure 84: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 5)
Figure 85: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 6)
Figure 86: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 7)
Figure 87: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 8)
Figure 88: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 9)
Figure 89: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 10)


More Publications